[Clinical remission in @entity309 : Data from the early XXXX cohort study CAPEA].

@entity1 @entity625 @entity1499 @entity309 @entity617
OBJECTIVE: To evaluate remission rates and therapeutic strategies in the routine care of early @entity309 . METHODS: Between 2010 and 2013, a  total of 1,301  @entity1 with early @entity625 were followed by 89 rheumatologists for up to 2  years in an early @entity625 cohort (CAPEA). Complete 2-year data are available for 669 @entity1 with @entity309 . RESULTS: Ninety-three percent of @entity1 were diagnosed with a moderate or high disease activity score (DAS28 >  3.2). Within 6  months, 40   % were in clinical remission (DAS28 <  2.6) and 21   % reached a low disease activity score (DAS28 >  2.6 to <  3.2). This proportion did not substantially increase during the 2-year follow-up. @entity1499 was the standard first-line treatment in 82   % of @entity1 . During follow-up, 10   % were treated with a  combination of disease-modifying antirheumatic drugs (DMARDs) and 12   % with biological agents. In 60   % of the @entity1 who did not reach remission within 3  months (and 54   % of @entity1 without remission by 6  months), treatment was not changed. At the beginning, 77   % of @entity1 were treated with glucocorticoids at different starting doses (26   % <  7.5  mg, 29   % 7.5-20  mg, and 45   % >=   20  mg of @entity617 per day). After 2  years, 47   % remained on glucocorticoids. CONCLUSION: While 40   % of @entity1 achieved clinical remission through standard care within 6  months, disease activity remained moderate to high in 37   % of @entity1 at 2  years. In these @entity1 a more consistent application of treatment may have increased the response rates.
